Neuro-Complex & Multi Supplements for Migraine Prevention

The goal of this prospective, monocentric, open-label, non-randomized and single arm study is to evaluate a reduction of migraine days per months (MDM) by 25% by using the combined supplementation with Neuro-Complex \& Multi after 8 weeks of product intake on participants with diagnosis of migraine meeting the criteria of the International Classification of Headache Disorders (ICHD-3) (with or without aura). The main endpoint of this clinical trial is : The mean changes in migraine days per month (MDM) after 8 weeks of supplementation. Participants will: Orally consume two caps of each product (taken at the same time) daily, one in the morning and one at the lunchtime preferably during meal, for 8 weeks after a running period of 8 weeks without supplementation. Intake will be initiated from the day of follow-up visit (V1) after all study procedures being performed until the day of the end-of-study visit (V2).

NCT Number	NCT07015411
Lead Sponsor	Benfida, a department of Handi-Move Collaborators: Artialis
Conditions	Migraine Headache, Migraine, Migraine in Adults
Enrollment	120 participants
Start Date	2025-05-15
Primary Completion	2025-12-15 (estimated)
Study Completion	2025-12-16 (estimated)
Updated on ClinicalTrials.gov	2025-06-11